EVENT – Page 2 – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson Halts Phase II Dengue Study Amid Shift in R&D Priorities

8 months ago talkbio0Tagged Antiviral Agents, Communicable Diseases, Dengue Study, Johnson and Johnson, mosnodenvir, Phase II, Priorities, R&D

Johnson & Johnson, Dengue Study, Phase II, Antiviral Drug, Mosnodenvir, Infectious Diseases, R&D Priorities

Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns

9 months ago talkbio0Tagged Anemia, Sickle Cell, Clinical Trials, concerns, Event, Fatal, Generalized, Market, Oxbryta, Pfizer, Safety, vaso-occlusive crises, Withdraw (activity)

Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events

Vicebio Secures $100 Million Funding to Advance Multivalent Respiratory Virus Vaccines

9 months ago talkbio0Tagged Combo, Human Metapneumovirus, Molecular Clamp Technology, multivalent, Respiratory syncytial virus, Respiratory viruses, Series B funding round, Vaccines, Vicebio

Vicebio, Multivalent Respiratory Virus Vaccines, $100 Million Funding, Series B Funding Round, Molecular Clamp Technology, RSV and hMPV Vaccine Combo

Autobahn Therapeutics Advances to Phase II for Mood Disorders with $100M Financing

11 months ago talkbio0Tagged Autobahn Therapeutics, Drug Industry, financing characteristics, Phase II

Autobahn Therapeutics, Phase II, Mood Disorders, Financing, Pharmaceutical Industry

Myricx Secures $114M Funding with Lilly’s Support for ADC Development

11 months ago talkbio0Tagged ADCs, biotech, Eli, Eli Lilly, Myricx, Series

Myricx, Eli Lilly, ADCs, Biotech Funding, Series A

Curie.Bio Raises $380M to Support Early-Stage Biotechs

12 months ago talkbio0Tagged accelerator, Bio, biotechs, Borisy, Curie, Early-stage, Series, venture, Weinberg, Zach

Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg